Insider Buying: Bluejay Diagnostics (NASDAQ:BJDX) Director Buys $25,000.00 in Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Donald Chase bought 12,500 shares of the business’s stock in a transaction on Saturday, March 14th. The shares were acquired at an average price of $2.00 per share, with a total value of $25,000.00. Following the completion of the purchase, the director directly owned 12,525 shares of the company’s stock, valued at approximately $25,050. The trade was a 50,000.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Bluejay Diagnostics Price Performance

NASDAQ BJDX opened at $1.78 on Thursday. The business has a fifty day moving average price of $1.89 and a two-hundred day moving average price of $3.09. Bluejay Diagnostics, Inc. has a fifty-two week low of $1.62 and a fifty-two week high of $16.68. The stock has a market capitalization of $1.83 million, a PE ratio of -0.15 and a beta of 0.72.

Bluejay Diagnostics (NASDAQ:BJDX) last released its earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. 18.47% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.